{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:16:45Z","timestamp":1784791005527,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jiac.2017.05.005","type":"journal-article","created":{"date-parts":[[2017,6,3]],"date-time":"2017-06-03T23:15:28Z","timestamp":1496531728000},"page":"556-562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["A randomized controlled trial of sitafloxacin vs. ertapenem as a switch\u00a0therapy after treatment for acute pyelonephritis caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli: A pilot study"],"prefix":"10.1016","volume":"23","author":[{"given":"Chitprasong","family":"Malaisri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angsana","family":"Phuphuakrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arrug","family":"Wibulpolprasert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pitak","family":"Santanirand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasisopin","family":"Kiertiburanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1A","key":"10.1016\/j.jiac.2017.05.005_bib1","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1016\/S0002-9343(02)01054-9","article-title":"Epidemiology of urinary tract infections: incidence, morbidity, and economic costs","volume":"113","author":"Foxman","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.jiac.2017.05.005_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1067\/mda.2003.8","article-title":"The etiology of urinary tract infection: traditional and emerging pathogens","volume":"49","author":"Ronald","year":"2003","journal-title":"Dis Mon"},{"issue":"Suppl D","key":"10.1016\/j.jiac.2017.05.005_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/41.suppl_4.25","article-title":"\u03b2-Lactamase-mediated resistance and opportunities for its control","volume":"41","author":"Livermore","year":"1998","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2017.05.005_bib4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1017\/ice.2015.239","article-title":"Increasing incidence of extended-spectrum \u03b2-lactamase-producing Escherichia coli in community hospitals throughout the southeastern United States","volume":"37","author":"Thaden","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jiac.2017.05.005_bib5","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/JCM.39.6.2206-2212.2001","article-title":"Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum \u03b2-lactamases: implications for the clinical microbiology laboratory","volume":"39","author":"Paterson","year":"2001","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jiac.2017.05.005_bib6","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum \u03b2-lactamases: a clinical update","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jiac.2017.05.005_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","article-title":"Extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: an emerging public-health concern","volume":"8","author":"Pitout","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2017.05.005_bib8","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1586\/14787210.6.5.671","article-title":"Clinical significance of extended-spectrum beta-lactamases","volume":"6","author":"Rodr\u00edguez-Ba\u00f1o","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jiac.2017.05.005_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0255-0857(21)02884-X","article-title":"Extended spectrum \u03b2-lactamases (ESBL) \u2013 an emerging threat to clinical therapeutics","volume":"22","author":"Chaudhary","year":"2004","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.jiac.2017.05.005_bib10","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.ajic.2006.05.238","article-title":"Resistance in gram-negative bacteria: Enterobacteriaceae","volume":"34","author":"Paterson","year":"2006","journal-title":"Am J Infect Control"},{"issue":"Suppl 4","key":"10.1016\/j.jiac.2017.05.005_bib11","doi-asserted-by":"crossref","first-page":"S273","DOI":"10.1086\/430789","article-title":"Extended-spectrum \u03b2-lactamases","volume":"41","author":"Turner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2017.05.005_bib12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0732-8893(01)00320-0","article-title":"MYSTIC program: summary of European data from 1997 to 2000","volume":"41","author":"Goossens","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.jiac.2017.05.005_bib13","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1086\/320182","article-title":"Variations in the prevalence of strains expressing an extended-spectrum \u03b2-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region","volume":"32","author":"Winokur","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2017.05.005_bib14","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(10)70143-2","article-title":"Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study","volume":"10","author":"Kumarasamy","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2017.05.005_bib15","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1001\/jama.2008.896","article-title":"Carbapenem-resistant Enterobacteriaceae: a potential threat","volume":"300","author":"Schwaber","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jiac.2017.05.005_bib16","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1128\/CMR.14.4.933-951.2001","article-title":"Extended-spectrum \u03b2-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat","volume":"14","author":"Bradford","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jiac.2017.05.005_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1053\/srin.2002.34689","article-title":"Pseudomonas aeruginosa: resistance and therapy","volume":"17","author":"Cunha","year":"2002","journal-title":"Semin Respir Infect"},{"key":"10.1016\/j.jiac.2017.05.005_bib18","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4103\/0974-7796.130543","article-title":"Complicated urinary tract infection caused by extended spectrum beta-lactamase-producing Escherichia coli","volume":"6","author":"Ranjan","year":"2014","journal-title":"Urol Ann"},{"key":"10.1016\/j.jiac.2017.05.005_bib19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2165\/11207380-000000000-00000","article-title":"Sitafloxacin: in bacterial infections","volume":"71","author":"Keating","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.jiac.2017.05.005_bib20","first-page":"139","article-title":"Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States","volume":"2000","author":"Deshpande","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2017.05.005_bib21","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/jac\/32.6.877","article-title":"In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates","volume":"32","author":"Marshall","year":"1993","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2017.05.005_bib22","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1128\/AAC.44.4.1102-1107.2000","article-title":"In\u00a0vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates","volume":"44","author":"Milatovic","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.05.005_bib23","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1128\/AAC.48.4.1400-1401.2004","article-title":"Activities of newer quinolones against Escherichia coli and Klebsiella pneumoniae containing the plasmid-mediated quinolone resistance determinant qnr","volume":"48","author":"Wang","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.05.005_bib24","first-page":"346","article-title":"In\u00a0vitro susceptibilities to levofloxacin and various antibacterial agents of 12,919 clinical isolates obtained from 72 centers in 2007. [In Japanese]","volume":"62","author":"Yamaguchi","year":"2009","journal-title":"Jpn J Antibiot"},{"issue":"Suppl 2","key":"10.1016\/j.jiac.2017.05.005_bib25","first-page":"S6","article-title":"Comparative in\u00a0vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections","volume":"95","author":"Tiengrim","year":"2012","journal-title":"J\u00a0Med Assoc Thai"},{"key":"10.1016\/j.jiac.2017.05.005_bib26","series-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2010"},{"key":"10.1016\/j.jiac.2017.05.005_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0732-8893(94)90078-7","article-title":"Interpretive criteria for DU-6859a disk diffusion tests using 5-micrograms disks","volume":"18","author":"Jones","year":"1994","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2017.05.005_bib28","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/jac\/dkh218","article-title":"In\u00a0vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics","volume":"53","author":"Alhambra","year":"2004","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2017.05.005_bib29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1476-0711-6-6","article-title":"Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms","volume":"6","author":"Mody","year":"2007","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jiac.2017.05.005_bib30","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2165\/00019053-200018050-00004","article-title":"Cost analysis of an adult outpatient parenteral antibiotic therapy (OPAT) programme. A Canadian teaching hospital and Ministry of Health perspective","volume":"18","author":"Wai","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jiac.2017.05.005_bib31","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/jac\/dkp343","article-title":"Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective","volume":"64","author":"Chapman","year":"2009","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2017.05.005_bib32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1086\/380645","article-title":"Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum \u03b2-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin","volume":"38","author":"Endimiani","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2017.05.005_bib33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/jac\/37.1.203","article-title":"Treatment failure due to extended spectrum beta-lactamase","volume":"37","author":"Karas","year":"1996","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2017.05.005_bib34","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1128\/AAC.48.12.4574-4581.2004","article-title":"Bloodstream infections due to extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy","volume":"48","author":"Kang","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.05.005_bib35","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1128\/AAC.39.1.170","article-title":"Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers","volume":"39","author":"Nakashima","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.05.005_bib36","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.diagmicrobio.2011.03.021","article-title":"Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009\u20132010","volume":"70","author":"Hoban","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2017.05.005_bib37","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dki344","article-title":"Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey","volume":"56","author":"Arslan","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2017.05.005_bib38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s15010-011-0132-6","article-title":"Extended-spectrum \u03b2-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy","volume":"39","author":"Meier","year":"2011","journal-title":"Infection"},{"key":"10.1016\/j.jiac.2017.05.005_bib39","first-page":"1172","article-title":"A\u00a0prospective study of ceftriaxone treatment in acute pyelonephritis caused by extended-spectrum beta-lactamase-producing bacteria","volume":"91","author":"Suankratay","year":"2008","journal-title":"J\u00a0Med Assoc Thai"},{"key":"10.1016\/j.jiac.2017.05.005_bib40","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1358\/dot.2008.44.7.1219561","article-title":"Sitafloxacin hydrate for bacterial infections","volume":"44","author":"Anderson","year":"2008","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.jiac.2017.05.005_bib41","first-page":"81","article-title":"Comparative study on sitafloxacin and levofloxacin in complicated urinary tract infections","volume":"56","author":"Kawada","year":"2008","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2017.05.005_bib42","first-page":"36","article-title":"Double-blind comparative study of sitafloxacin versus levofloxacin in patients with respiratory tract infection","volume":"56","author":"Kobayashi","year":"2008","journal-title":"Jpn J Chemother"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X17301113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X17301113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:56:32Z","timestamp":1761159392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X17301113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1341321X17301113"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2017.05.005","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized controlled trial of sitafloxacin vs. ertapenem as a switch\u00a0therapy after treatment for acute pyelonephritis caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli: A pilot study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2017.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}